Department of Oncology and Haematology Azienda Ospedaliera Policlinico di Modena.
Novità nel campo della Genetica Medica
Genetic Helps us to Identify Patients at High Risk of Developing Breast and Ovarian Cancer
Genetics
• Genetics is the study of heredity
While genetics influence genomics, genetics is responsible for only 5-10% of breast cancer
• Genetics focuses primarily on the likelihood of developing cancer
• Genetic tests find mutations, not disease
Source: Understanding Cancer Series: Gene Testing, National Cancer Institute
Key point: whole body has the mutation
Knudson A, PNAS 1971
Two Hits Hypothesis
Genetic Theory of Cancer
• Cancer is a genetic disease
• Most cancers have mutations in multiple genes
• The underlying defect in cancers is Genomic Instability
• Cancers require alterations in genes involved in
cellular proliferation, cell cycle, apoptosis, telomere maintenance and DNA repair
• Most inherited cancer syndromes are due to alterations in genes required for genomic stability.
Knudson A, PNAS 1971
As an autosomal dominant syndrome, a deleterious BRCA mutation can be transmitted through maternal or paternal lineages. As an incomplete
penetrance gene, interacts with environment to develop cancer
SYNDROME TUMORAL SPECTRUM TRANSMISSION GENES BREAST/OVARY Breast, ovary, uterus, prostate,
stomach, colo-rectum, pancreas, bilious tract, melanoma
Dominant autosomal BRCA 1 BRCA2 LI-FRAUMENI Soft tissues, breast, bone, leukemya,
brain, adrenal Dominant autosomal P53
COWDEN Breast, tyroid, endometrium (amartomes)
Dominant autosomal
PTEN Diffuse Gastric
Cancer Stomach, Lobular Breast Dominant autosomal CDH1 HNPCC
(Lynch Syndrome)
Colo-rectum, ovary, endometrium, bladder, urinary tract, pancreas,
stomach, bilious tract, breast
Dominant autosomal MLH1 MSH2 MSH6
PEUTZ-JEGHERS Colo-rectum, stomach, ovary, testis, cervix, pancreas, breast
Dominant autosomal
LKB1
72%
69%
Tumor sites in families with TP53 germline mutations
% of all tumors
0 5 10 15 20 25 30
Breast Brain GI Hematol Other
Bone Soft Tissue Gynecologic
Adrenal
.
Cowden Syndrome Cancer Risks
Tumor Site Risk
Pilarski R.
JGC.2009;18:13-27
Risk
Tan et al. Clin Can Res.
2012;18(2):400-7
Breast 25-50% 85%
Thyroid 3-10% 35%
Endometrial 5-10% 28%
Renal Cell Unknown 34%
Melanoma Unknown 6%
Colon Unknown 9%
Cancer Type Age Range Cancer Risk Risk for General Population
Gastric (male) To age 80 67-70% 0.6%
Gastric (female) To age 80 56-83% 0.6%
Female Breast To age 50 10% 1.9%
To age 80 39-52% 10.2%
Colorectal To age 80 Possible
Increased Risk
3.0%
Hereditary Diffuse Gastric Cancer
0 20 40 60 80 100
0 20 40 60 80
Colorectal Endometrial Stomach Biliary tract Urinary tract Ovarian
78 43 19 18 10 9
%
Age (years)
Peutz-Jeghers Syndrome
Pancreatic Cancer
Liver
Lung
Breast
Ovary
Uterine Cancer
Testis
Others
Website for BRCA classification
◦ BRCA exchange
◦ ClinVar
◦ BIC
◦ LOVD
◦ HCI
◦ A-GVGD
Website for functional analysis of BRCA
• BRCA Circos
• LOVD BRCA1
• LOVD BRCA2
Cortesi et al., Breast Can Res Treat 2012
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer
phenotype
Zuntini et al., Oncotarget 2017
Prevention of tumorigenesis
DNA repair Protein
Ubiquitination
Regulation of transcription
Regulation of cell cycle
Repair of double strand DNA
breaks / DNA adducts
Mediates E2- dependent ubiquitination
Modulates gene
expression in response to cell stress
P21 DNA damage
Induces cell cycle arrest at the G1/S, S and G2/M
checkpoints
Cellular function regulated by BrCa1
BRCA1 tumor suppressor protein
BRCA2
RAD51
DNA damaging RAD51 forms nucleoprotein filaments
RAD51 RAD51
RAD51
RAD51 RAD51
BRCA1
BRCA1 is a DNA damaging “detector”, blocks the transcription by cell cycle arrest at the G1/S, S and G2/M checkpoints and by ubiquitination of FANCD1
otherwise induces the DSB repair by chromatin remodelling
Chk2 ATR ATM
Toss & Cortesi, 2013 A
L
F
C E G
D1 Ub
B
M
I
Methods
Presented By Arielle Heeke at 2017 ASCO Annual Meeting
Results, Total HRD mutation frequency by lineage
Presented By Arielle Heeke at 2017 ASCO Annual Meeting
Results, HRD mutation landscape by lineage
Presented By Arielle Heeke at 2017 ASCO Annual Meeting
Niraparib Plus Carboplatin in Patients with Homologous Recombination Deficient Advanced Solid Tumor Malignancies
Presented By Arielle Heeke at 2017 ASCO Annual Meeting
Multi-Gene (NGS) Panels
• Genetic tests to look at dozens of genes related to cancer
• Similar cost and turn around time as gene specific testing
• Higher risk of uncertain results
ACCE FRAMEWORK
Parameter Definition
Analytic Validity
How well test measures property or chracteristics it is intended to measure Clinical
Validity
Accuracy of the test in diagnosing or
predicting risk for health condition (sensitivity, specificity, PPV, NPV)
ELSI Ethical, Legal and Social Implication
ACTIONABILITY
Summary of Clinical Validity
GENE BREAST OVARY OTHER
ATM Y N ?Pancreas
CHEK2 Y N ?Colon
PALB2 Y N
?Pancreas
NBN Y (657del5) N
NF1 Y N
BRIP1 N Y
RAD51C/D N Y
BARD1 N Y
Normal ATM protein Function
• A Serine-Protein Kinase as p53 or BRCA1
• Senses Double Stranded Breaks in DNA
• Activates cell cycle checkpoints
• Mutant ATM causes A-T, a genomic instability syndrome, which is lethal by age 20.
• Mutant ATM heterozygotes have increased risk of
breast, leukemia, lymphomas and stomach cancer.
Gene Variant Tumor type
CHEK2 pI157T Br, CCR,
Pr, Kidney, Bladder CHEK2 c1000delC Br, CCR, Pr
CHEK2 pS428F Br
CHEK2 Cdel5395 Br, Pr
CHEK2 c.IVS2 + 1G > A Br, Pr, Tyr
C
28 30 21 11
Br: 49 ER+ PgR+
50
Br: 45 Br: 50 Br: 50
D: 51
Br: 50 72
Br: 55 D: 55
PALB2 in BRCA1&2 negative pts
Cancer
Type Age Range Cancer
Risk Risk for General
Population
Breast To age 80 Up to 30% 10.2%
Prostate To age 80 Increased
Risk 10.9%
NBN Gene Mutation
46
NF1 Gene
NF1 is a tumor suppressor gene
NF1 is located on Chromosome 17 long arm
- NF2 on other hand is located on Chromosome 22
NF1 gene encodes the protein
Neurofibromin
Relative Risk of cancers in NF1: UK
Overall risk of cancer was 2.7 times higher than in the general population
. Connective tissue SIR=122 (95% CI 7.8-24%)
Brain SIR=22.6 (95% CI 3.9-16%)
Breast SIR=1.87 (95% CI 0.61-4.37%)
Walker et al., 2006, Br J Can
The transfer of multigene panel testing for hereditary breast and ovarian cancer to
healthcare: What are the implications for the management of patients and families?
Eliade M et al., Oncotarget 2017
ASCO supports the
communication to patients of medically relevant incidental germline findings conducted in the clinical setting.
Oncology providers should communicate the potential for incidental germline
information to patients and should review the potential benefits, limitations, and risks before testing.
ASCO Policy Statement
NGS offers promise, but
poses significant challenges for oncologists who are ill
prepared to handle incidental findings that have clinical
implications for at-risk family members. This report
underscores the need for oncologists to develop a
framework for pre- and post- communication of risks to patients undergoing routine multi-gene panels testing
Ready for Surprises?
• All BRCA1 and BRCA2 pathogenic variants regardless of tumor type (NCCN guideline)
• Founder mutations (ie. MSH2 exon 1-6 deletion, TP53 R337H)
• Uncommonly mutated genes (ie. CHEK2, PALB2)
Germline Finding Report
N° of UV in different genes for patients
Kurian AW et al., JCO 2014
N° of UV per gene across 198 patients
Kurian AW et al., JCO 2014
Matsuzawa et al., Mol Cell 2014
BRCA1
BARD1
OLA1 ?
BRCA1
BARD1
OLA1 E168Q
?
OLA1
mutation BRCA1 mutation
BRCA1 I62V
BARD1
OLA1
?
BRCA1
BARD1 V695L
OLA1 ?
BARD1 mutation
Modified by Chiba N
H.Chen et al., Scient Rep 2015
Genome-wide association analysis of more than 120,000
individuals identifies 15 new susceptibility loci for breast cancer
Michailidou, Nat Gen 2015
CONCLUSIONS
• Oncogenetic counselling as prediction of treatment response and mutation carrier
• HRD analysis by NGS for PARP-inhibitor using
• Role for MGPs in individuals who are negative for hereditary syndrome but with suggestion for
susceptibility
• Refer results only for «actionable» genes
• A professional genetic expertise needs for MGPs
• GWA will be able to identify new susceptibility loci
for BC
BRCA1 Germline
8%
BRCA2 Germline
6%
BRCA1 Somatic
3% BRCA2 Somatic
3%
BRCA1 Methylation
11%
EMSY Amplification PTEN Loss 6%
Other HRD 5%
7%
CCNE1 Amplification
15%
MMR Germline
2%
Other 34%
HR deficiency No HR deficiency
Levine, D. The Cancer Genome Atlas, Molecular profiling of serous ovarian cancer. 2011
BRCA Mutation 31% (14%germline)
Others HR deficiency
18%
Gabai-Kapara E et al. ( 2014)
45 74 84 3% 50% 55%
45 74 84 1% 17% 65%
BRCA2
RAD51
DNA damaging RAD51 forms nucleoprotein filaments
RAD51 RAD51
RAD51
RAD51 RAD51
BRCA1
BRCA1 is a DNA damaging “detector”, blocks the transcription by cell cycle arrest at the G1/S, S and G2/M checkpoints and by ubiquitination of FANCD2
otherwise induces the DSB repair by chromatin remodelling
Chk2 ATR ATM
Toss & Cortesi, 2013
A L
F
C E G
D2 Ub
B
M
I
Santos-Pereira J. et al. Nat. Publ. Gr. (2015)
PARP
Inhibition of PARP-1
prevents recruitment of repair
factors to repair SSB
XRCC1
LigIII PNK 1
pol β
Replication (S-phase)
DNA DSB
DNA SSB
REPAIR
CELL SURVIVAL
CELL DEATH
BRCA deficient PARP
inhibitors
PARP inhibitors
Toss & Cortesi, 2013
Chemosensitivity/resistance
Tassone P. et al.; 2003:88; 1285-1291
N N O
N O
N O
F
IC50 on PARP-1 = 4.9 nM IC50 on PARP-2 ≈ 5nM IC50 on PARP-3 ≈ 50nM IC50 on Tankyrase >1M
• Olaparib (AZD2281; KU-0059436)
• Favorable PK
• Good bioavailability across species
• Tumor PK -Significant levels at 24 hrs following single oral dose
Menear et al. J Med Chem 2008
Olaparib: an Oral Inhibitor of
Poly (ADP-ribose) Polymerase (PARP)
BRCA2 +/- BRCA2 -/- Wild type
Log
surviving fraction
- 4 0 - 3 - 2 - 1 0
PARP inhibitor concentration (M)
10-9 10-8 10-7 10-6 10-5 10-4
Increased levels of chromosomal aberrations in PARP inhibitor
treated BRCA2 -/- cells
WT BRCA-/- 0
1 2 3 4
BRCA2-/- + PARPi WT
+ PARPi
Mean number of chromatid aberrations per cell
Chromatid breaks Complex aberrations
Farmer et al. Nature 2005; 434:917-21
BRCA 1 & 2
-/-ES Cells are Very Sensitive to
PARP Inhibition
Sono eleggibili al test BRCA tutte le pazienti con diagnosi di carcinoma epiteliale ovarico non mucinoso e non borderline, di carcinoma delle tube di Falloppio e di carcinoma peritoneale primitivo per completare la fase diagnostica molecolare in previsione di un eventuale utilizzo terapeutico e per favorire l’accesso ad una consulenza pre-test nell’ambito dei percorsi di prevenzione.
…Si sottolinea la necessità di definire percorsi aziendali in cui vengano indicate in modo chiaro per le pazienti ed i loro familiari, le funzioni e le responsabilità dell’equipe oncologica, del laboratorio e dell’equipe di genetica clinica oncologica nelle varie fasi del percorso individuato….
Breast Ovarian Cancer (BOC): Pazienti affette da BC e OC
Hereditary Ovarian Cancer (HOC): 2 o più pazienti affette da OC, con parentela di I grado e su 2 diverse generazioni
Sospetto ereditario per carcinoma mammario e/od ovarico (SHBOC):
3 o più pazienti affetti da BC e OC con parentela di I grado senza giovane età o bilateralità, oppure senza parentela di I grado e con giovane età o bilateralità
Hereditary Breast/Ovarian Cancer (HBC/HBOC): 3 o più pazienti affetti da BC (e OC), di cui uno con BC entro i 40 anni o bilaterale e parentela di I grado tra i 3 individui
Early Onset Breast Cancer (EOBC):
Pazienti affette da BC entro i 35 anni di età
Male Breast Cancer (MBC): Paziente affetto da BC maschile
Familiare per carcinoma mammario e/od ovarico (FBOC): 3 pazienti affetti da BC ed OC senza essere HBOC o SHBOC
Fortemente sospette per familiarità (SFBC+/SFBOC+/SFBOC): 2 parenti di I grado di cui 1 con età ≤ 40 anni o bilaterale oppure 1 paziente affetta da BC ≤ 40 anni o bilaterale e 1 da OC con familiarità di I
grado oppure 1 BC e 1 OC con parentela di I grado Triple Negative Breast Cancer (TNBC) < 60 anni Carcinoma Ovarico Non Mucinoso e Non Border-line
BRCAPRO o Tyrer-Cuzick > 40% in donna sana
CRITERI PER ACCEDERE AL TEST
Il test BRCA deve essere richiesto per la ricerca di varianti patogenetiche costituzionali e va valutata l’eventuale fattibilità del test BRCA somatico. Per un’adeguata esecuzione del test è necessaria per i laboratori una comprovata validazione ed un controllo di qualità esterno del test proposto
Mafficini A et al,. Oncotarget. 2016 Jan 12;7(2):1076-83
17%
6%
77%
Germline Mutation ( 9 )
Somatic mutation (3)
NON PATHOGENIC (40)
PROPORTION OF PATHOGENIC
VARIANTS, NON-PATHOGENIC VARIANTS IN TESTING SEROUS HIGH GRADE OC
BRCA1/2
Stili di vita e prevenzione
dei tumori
Biosintesi degli Estrogeni
20,22-Lyase
11b-Hydroxylase
18-Hydroxylase
17,20 Lyase
Pharmacological Target Cholesterol
Pregnenolone
Progesterone
11-Deoxycorticosterone
Corticosterone
17a-Hydroxylase
21a-Hydroxylase
11-Deoxycortisol
Testosterone Dehydroepiandrosterone
Androstenedione
Cortisol
Aldosterone
AROMATASI
Oestrone Oestradiol
(intermediate)
(intermediate) 17a-
Hydroxypregnenolone
17a-
Hydroxyprogesterone
Attività dell’ enzima aromatasi
ANDROGENS OESTROGENS
P-450 Aromatase
+ NADPH-cytochrome P-450 reductase
(Testosterone, androstenedione, 16-OH-testosterone)
(Oestradiol, oestrone)
tumour
growth
Breast Cancer Tumorigenesis
Situazione nutrizionale – pool di Asl 2009-12 (n=149.823)
Popolazione in eccesso ponderale
Sovrappeso* 31,4 %
Obeso** 10,5 %
Consigliato di perdere peso da un medico o operatore sanitario***
Sovrappeso 43,6%
Obesi 77,8 %
*sovrappeso = indice di massa corporea (Imc) compreso tra 25 e 29,9
**obeso = indice di massa corporea (Imc) ≥30
***tra coloro che sono stati dal medico negli ultimi 12 mesi
Attività fisica – pool di Asl 2009-2012 (n=147.020)
* lavoro pesante oppure adesione alle linee guida (30 minuti di attività moderata per almeno 5 giorni alla settimana, oppure attività intensa per più di 20 minuti per almeno 3 giorni)
** non fa lavoro pesante, ma fa qualche attività fisica nel tempo libero, senza però raggiungere i livelli raccomandati
*** non fa un lavoro pesante e non fa nessuna attività fisica nel tempo libero
Livello di attività fisica
Attivo* 33,1 %
parzialmente attivo** 35,7 %
Sedentario*** 31,1 %
The highest adherence score to an MD was significantly associated with
a lower risk of all-cause cancer mortality (RR: 0.87), colorectal cancer (RR: 0.83), breast cancer (RR: 0.93), gastric cancer (RR: 0.73), prostate cancer (RR: 0.96), liver cancer (RR: 0.58), head and neck cancer (RR: 0.40), pancreatic cancer (RR:
0.48),and respiratory cancer (RR: 0.10)
Cancer Med. 2015
1,784,404 subjects included in 56 studies
Toledo et al. JAMA Internal Medicine 2015
The multivariable-adjusted hazard ratios vs the control group were 0.32 (95%CI, 0.13-0.79) for the Mediterranean diet with extra-virgin olive oil group
and 0.59 (95% CI, 0.26-1.35) for the Mediterranean diet with nuts group
4282 women Follow up: 4,8 ys
Soy isoflavones consumption was inversely associated with risk of breast cancer incidence
(RR = 0.89, 95% CI: 0.79–0.99)
The protective effect of soy was only observed among studies conducted in Asian populations (RR = 0.76, 95% CI: 0.65–0.86) but not in Western
populations (RR = 0.97, 95% CI: 0.87–1.06)
Jia-Yi Dong • Li-Qiang Qin. Breast Cancer Res Treat (2011)
Soy intake consistent with a traditional Japanese diet (2-3 servings daily, containing 25-50 mg isoflavones) appears safe for breast
cancer survivors
While there is NO clear evidence of harm, better evidence confirming safety is required before use of high dose (≥ 100mg) isoflavones can
be recommended for breast cancer patients
MODERATE soy consumption appears to be safe and possibly beneficial for most women
Heidi Fritz. PLOS ONE. November 2013
Soy consumption may be associated with reduced risk of breast cancer incidence, recurrence, and mortality
Cancer 2017
a higher dietary intake of isoflavone was associated with reduced all-cause mortality
A 21% decrease was observed in all-cause mortality for women who had the highest versus lowest quartile of
dietary isoflavone intake
(>1.5 vs<0.3mg daily: HR, 0.79; 95% CI, 0.64-0.97; Ptrend 5.01)
6235 women with BC F-up approx. 9.4 ys1224 deaths documented
WCRF / AICR. CUP: Diet, Nutrition, Physical Activity and Breast Cancer Survivors. 2014
Linee guida sulla nutrizione
e l’attività fisica per la prevenzione dei
tumori.
American Cancer Society
© 2012 American Cancer Society
Studio su base di popolazione del Body mass index
Il RTM ha intrapreso uno studio relativo all’influenza del body mass index sul rischio di neoplasia mammaria.
Grazie alla collaborazione dei centri di screening è stato possibile effettuare misurazioni di altezza e peso delle donne invitate al programma di screening
mammografico.
Risultati su 14.255 donne:
N° Casi SIR Normopeso 6443 49 1.25 Sovrappeso 5334 60 1.85*
Obesità 2478 27 1.79*
* statisticamente significativo
Sebastiani F. J Breast Cancer 2016
Increased incidence and poor prognosis of breast cancer in postmenopausal women with high Body Mass Index
attending to the Mammography Screening Program in the province of Modena (Italy)
Normal weight Overweight Obesity
Normal weight Over weight Obesity
Sebastiani F. J Breast Cancer 2016
J Clin Oncol 2010
Obesity is an independent prognostic factor for
developing distant metastases and for death as a result of breast cancer
On a long-term basis, adjuvant therapy seemed to be
less effective for patients with breast cancer and obesity
.After 10 years, both chemotherapy and endocrine therapy seemed to be less effective in patients with BMIs of 30 kg/m2 or greater
HR for death (all causes) in relation to follow-up time, BMI, and adjuvant treatment
J Clin Oncol 2010
J Clin Oncol 2010
ATAC study: 9366 postmenopausal women with early-stage breast cancer randomly assigned to oral daily anastrozole alone, tamoxifen alone, or
the combination in a double-blind fashion
There is a significantly greater risk of recurrence in overweight women receiving anastrozole
women with a high BMI at baseline had more recurrences
than those women with a low BMI (adjusted HR, 1.39) and
significantly more distant recurrences (adjusted HR, 1.46)
Is estrogen suppression with anastrozole complete in obese women?
J Clin Oncol 2010
LISTA DEGLI INVESTIGATORI
Sperimentatore principale Massimo Federico¹
Co-sperimentatore di riferimento Federica Sebastiani¹
Co-sperimentatori e collaboratori Nino Battistini¹, Silvia Toni¹
¹ Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica. Università di Modena e Reggio Emilia
Programma di educazione alimentare e al movimento rivolto alle donne operate per carcinoma della mammella
Obiettivi: valutare l’ efficacia di un programma di educazione alimentare e al movimento su:
parametri antropometrici (BMI, peso corporeo)
Livello di attività fisica
Miglioramento della qualità di vita
OBIETTIVI
Analisi attività ambulatoriale Gen 2010-Mag 2016
Variabili considerate
BODY MASS INDEX (Kg/m2)
ATTIVITÀ FISICA PROGRAMMATA (ore/settim)
ANALISI STATISTICA Anova per misure ripetute
Campione
N°donne sottoposte alla prima visita: 442 N°donne con un follow-up di 24 mesi: 442
* differenza statistica con p<0.05
Campione: donne (n=442) con un f-up mediano di 24 mesi
Analisi per strato di BMI
103
170 169
103
150
130 103
150
125 103
135
115
Normopeso Sovrappeso Obese
P=0.74
P<0.001*
P<0.001*
103 donne
170 donne
169 donne
BMI (kg/m2 )
Base 6 M 12 M 24 M
0,00 0,50 1,00 1,50 2,00 2,50 3,00 3,50
BASELINE 6 MESI 12 MESI 24 MESI
* differenza statistica con p<0.05
ore/settim
P<0.001*
Attività fisica media
Campione: donne (n=442) con un f-up mediano di 24 mesi
Conclusioni
• L’analisi preliminare dei dati raccolti in 6 anni di attività dimostra come una corretta alimentazione ed un regolare esercizio fisico possono favorire una significativa riduzione del peso corporeo
• Il controllo del peso e del livello di attività fisica
attraverso strategie di intervento sullo stile di vita
dovrebbe rappresentare parte integrante del follow
up delle pazienti con tumore della mammella
Costi sanitari pubblici
Trattamenti
e cure Prevenzione
Ogni investimento in prevenzione produce, nel corso degli anni successivi, un risparmio triplo in trattamenti e cure
Prof. Cascinu Stefano Dr. Cortesi Laura
Dr. Toss Angela Dr Spaggiari Federica Dr. Razzaboni Elisabetta
Dr. Marchi Isabella Dr. Medici Veronica Dr. Venturelli Marta Inf. Bevini Paola
Prof. Pietro Torricelli Dr. Rachele Battista Dr. Barbara Canossi Dr. Annarita Pecchi Dr. Dal Molin Chiara Dr. Antonella Drago Dr. Giovanni Grandi
Programmi di screening di popolazione
Gratuiti, ad invito
Indicazioni dell’Unione Europea e del Ministero della Salute
Donne fra i 45 ed i 74 anni
Mammografia annuale in due
proiezioni dai 45 ai 50 anni poi
biennale
Learning Objectives
• To distinguish between role of Genetics and Genomics in clinical practice
• Focus on Hereditary Breast Cancer Syndromes and Multi-Gene Panels
• To explain the clinical meaning of Moderate Gene Risk and VUS
• To identify the patients for whom the Oncotype DX assay has been clinically validated
• To identify the patients for whom the Mammaprint assay could spare the chemotherapy
• To describe the most frequent mutated genes in
sub-type breast cancer and resistance mechanisms
by NGS
Examples of Genetic and Genomic Tests
Genetic Test
• BRCA1 and BRCA2
• The genetic make up of patients is tested for BRCA1 and BRCA2 mutations. Patients with those mutations have higher chances of developing breast cancer.
Genomic Test
• Oncotype DX® Breast Cancer Assay
• The expression level of 21 genes is measured in tumor tissue from patients that have already been diagnosed with breast cancer. This assay evaluates if a patient is going to recur (prognostic) and predicts benefit from chemotherapy and hormonal therapy (predictive)
• Mammaprint assay
• Breast Cancer Index
Moderate Risk Genes
Cancer risks may not be very high
◦ How high does risk need to be before we pursue surgery or medications?
Cancer risks may be unclear
◦ How do we make medical decisions when we don’t know the risks?
We’re still learning
◦ The recommendations you get today may be
different in 5 years
Results of Multi-Gene Panel Testing N=76574
Gene N % with mutations
CHEK2 641 0,84
ATM 503 0,66
PALB2 392 0,51
BRIP1 216 0,28
NBN 140 0,18
RAD51C/D 163 0,21
BARD1 47 0,14
Total 2164 2,54
Real World Classification can be Messy
[NOME CATEGORIA]
[NOME CATEGORIA]
[NOME CATEGORIA]
[NOME CATEGORIA]
RESULTS
32%
37%
5%
27%
First 599 of 1400 patients in the PROMPT registry-compared testing results to classification in CLINVAR
Development of Functional Assays
• Most variants of uncertain significance have only been observed in a small number of families
• These VUS will not be readily classified by epidemiological approaches
• Functional assays offer a useful option for evaluating these VUS
• Must use assay associated with risk associated protein activity
• Sensitivity and specificity are required
Br: 33 49
47 Stomach: 54
Oncotype DX® 21-Gene
Recurrence Score® (RS) Assay
PROLIFERATION Ki-67
STK15 Survivin Cyclin B1 MYBL2
ESTROGEN ER
PR Bcl2
SCUBE2 INVASION
Stromelysin 3 Cathepsin L2
HER2 GRB7 HER2
BAG1 GSTM1
REFERENCE Beta-actin GAPDH RPLPO GUS TFRC CD68
16 Cancer and 5 Reference Genes From 3 Studies
Oncotype DX ® 21-Gene
Recurrence Score ® (RS) Assay
RS = Coefficient x Expression Level + 0.47 x HER2 Group Score - 0.34 x ER Group Score
+ 1.04 x Proliferation Group Score + 0.10 x Invasion Group Score
+ 0.05 x CD68 - 0.08 x GSTM1 - 0.07 x BAG1
Calculation of the Recurrence Score Result
Category RS (0-100) Low risk RS <18
Int risk RS ≥18 and <31 High risk RS ≥31
The Trial Assigning Individualized Options for Treatment (TAILORx)
This trial was designed to further validate and refine the clinical usefulness of the 21-gene assay (Oncotype DX Recurrence Score, Genomic Health) in a specified low-risk cohort of women with hormone-receptor–positive, HER2-negative, axillary node–negative invasive breast cancer.
Node N-, ER+ Breast Cancer
RS <10 Hormone
Therapy Registry
RS 11-25 Randomize Hormone Rx
vs
Chemotherapy + Hormone Rx
RS >25
Chemotherapy +
Hormone Rx
Oncotype DX
®Assay
Register Specimen banking
Primary study group
TAILORx Schema
Invasive Disease–free Survival
5-year event rate in cancers with recurrence scores 10 or less they did not receive chemotherapy
Freedom from Recurrence of Breast Cancer at Distant Site
Freedom from Recurrence
at Any Site Overall Survival
Among patients with hormone-receptor-positive, HER2- negative, axillary node-negative breast cancer who met established guidelines for the recommendation of
adjuvant chemotherapy on the basis of clinicopathologic
features, those with tumors that had a favorable gene-
expression profile had very low rates of recurrence at 5
years with endocrine therapy alone.
The Winners are…
1.
2.
3.
4.
5.
N+
2.86 0.004T>2
1.55 0.003GIII
1.43 0.005HER2
1.56 0.001ER
1.43 0.007HR p
0.00 0.25 0.50 0.75 1.00
159 61 21 2
5/7
378 195 75 7
3-4
1549 914 343 32
0/2 Number at risk
2 5 8 10
0/2 3-4 5/7
A
0.00 0.25 0.50 0.75 1.00
88 42 8 2
5/7
210 108 26 1
3-4
675 372 113 8
0/2 Number at risk
2 5 8 10
0/2 3-4 5/7
B
Cumulative relapse probability
Follow-up, years
Tumor size, node status, grading, HER2 and
estrogen receptor status still retain a strong
value in patients with operable breast cancer
diagnosed in recent years
The MINDACT Study:Patient Enrollment
Enrolled N=6693
Clinical Risk:
Adjuvant Online
Genomic Risk:
Mammaprint
C low/G low
N=2745
Discordant
N=592 N=1550
C low/G high C high/G low C high/G high
N=1806 Random
No chemotherapy Chemotherapy
N=644
Clinical Outcome at 5-y Median Follow-up:
Concordant Risk Group
cL/gL 97.6% (96.9-98.1) cH/gH 90.6% (89.0-92.0)
92.8% (91.7-93.7) 85.3% (83.4-87.0)
98.4% (97.8-98.9) 94.7% (93.4-95.7)
The MINDACT Population: CT according Clinical or Genomic Strategy
Whole Population:
N=6693
N=2745 cLow/gLow
N=1806 cHigh/gHigh
Discordant
N=592 cLow/gHigh
N=1550 cHigh/gLow Clinical Strategy
CT=1550+1806=3356
Genomic Strategy CT=592+1806=2398 14% CT reduction
• MINDACT study provide a level 1A of evidence of the clinical utility of Mammaprint for assessing the lack of CT benefit in cHigh Risk population
• cHigh/gLow patients have a 5-y DMFS rate of excess of 94% regardless CT
• In the whole population genomic strategy leads to a 14% CT reduction compared with clinical strategy
• Among the cHigh Risk patients the clinical use of
Mammaprint is associated with a 46% CT reduction
HOXB13/IL17BR (H/I), is a prognostic biomarker in both untreated and tamoxifen-treated early-stage ER+ breast cancer patients.
Expression of H/I within primary tumors was determined by reverse-transcription polymerase chain reaction with a prespecified cutpoint. The predictive ability of H/I for
ascertaining benefit from letrozole was determined using multivariable conditional logistic regression including standard clinicopathological factors as covariates.
• Patients with High H/I had a 5yr absolute benefit of 16.5% from extended endocrine therapy with Letrozole (p=0.007)
• Patients with Low H/I had no significant benefit from extended endocrine therapy with Letrozole (p=0.35)
Prognostic ability of BCI, 21-gene recurrence score, and IHC4 for overall 10 year distant recurrence, for all patients and according to ATAC treatment group.
BCI-L (linear) was the only significant prognostic test for risk of both early and late distant recurrence. It could help to identify patients at high risk for late
distant recurrence who might benefit from extended endocrine or other therapy.
Sgroi DC et al. Lancet Oncol 2013
Tumor and normal interstitial fluid proteomic characterization in breast cancer patients receiving neoadjuvant chemotherapy
NGS meta-analysis: most frequently mutated
genes in each molecular subtype
Mechanisms of resistance to HER2- targeted therapy:
1. Impaired access to HER2 by expression of extracellular domain- truncated HER2 (p95 HER2) or overexpression of MUC4
2. Alternative signaling from IGF-1R and other HER family members or MET
3. Loss of downstream controllers (PTEN, p27)
4. Activation of downstream signaling pathways (PI3K-Akt, MAPK, mTOR)
Mechanisms of resistance to endocrine therapy:
1. Hyperactivation of the PI3K/AKT/mTOR pathway 2. Dysregulation of normal cell cycle control
3. Downregulation of ER through epigenetic aberrations (i.e. DNA methylation) 4. Amplification or overexpression of the ERBB2 proto-oncogene.
GENES PROTEINS
ERBB2 HER2
EGFR EGFR
HER3 HER3
AKT1 AKT2 AKT3
mTOR mTOR
PIK3CA PTEN
IGF1R ; FGFR1 ; MET IGF1R ; FGFR1 ; MET TP53 ; RB1
BRAF ; RAF1 KRAS ; NRAS
MEK1 (MAP2K1) ; MEK2 (MAP2K2)
ERK1 (MAPK3) ; ERK2 (MAPK1) ERK1 (MAPK3) ; ERK2 (MAPK1 MAP3K1
CCND1 CCND2 CCND3 CDK4 ; CDK6
ESR1